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To analyze national prevalence, genomovar distribution, and epidemiology of the Burkholderia cepacia complex in
Italy, 225 putative B. cepacia complex isolates were obtained from 225 cystic fibrosis (CF) patients attending
18 CF centers. The genomovar status of these isolates was determined by a polyphasic approach, which
included whole-cell protein electrophoresis and recA restriction fragment length polymorphism (RFLP) anal-
ysis. Two approaches were used to genotype B. cepacia complex isolates: BOX-PCR fingerprinting and pulsed-
field gel electrophoresis (PFGE) of genomic macrorestriction fragments. A total of 208 (92%) of 225 isolates
belonged to the B. cepacia complex, with Burkholderia cenocepacia as the most prevalent species (61.1%). Clones
delineated by PFGE were predominantly linked to a single center; in contrast, BOX-PCR clones were composed
of isolates collected either from the same center or from different CF centers and comprised multi-
ple PFGE clusters. Three BOX-PCR clones appeared of special interest. One clone was composed of 17
B. cenocepacia isolates belonging to recA RFLP type H. These isolates were collected from six centers and
represented three PFGE clusters. The presence of insertion sequence IS1363 in all isolates and the comparison
with PHDC reference isolates identified this clone as PHDC, an epidemic clone prominent in North American
CF patients. The second clone included 22 isolates from eight centers and belonged to recA RFLP type AT. The
genomovar status of strains with the latter RFLP type is not known. Most of these isolates belonged to four
different PFGE clusters. Finally, a third clone comprised nine B. pyrrocinia isolates belonging to recA RFLP
type Se13. They represented three PFGE clusters and were collected in three CF centers.
In the late 1970s and 1980s, reports on the recovery of
Burkholderia cepacia from cystic fibrosis (CF) specimens be-
gan to appear (29), and the emergence of this pathogen was
subsequently reviewed (25, 35, 36). Polyphasic taxonomic stud-
ies identified bacteria tentatively classified as B. cepacia as a
complex of at least nine closely related species (genomovars).
This B. cepacia complex consists of B. cepacia, Burkholderia
multivorans, Burkholderia cenocepacia, Burkholderia stabilis,
Burkholderia vietnamiensis, Burkholderia dolosa, Burkholderia
ambifaria, Burkholderia anthina, and Burkholderia pyrrocinia
(representing genomovars I through IX, respectively) (10, 11,
64–67).
From the first description of the occurrence of different
genomovars in CF patients (64), it was evident that all
B. cepacia complex species were potentially capable of human
infection. Studies of the distribution of B. cepacia complex
species in CF patients revealed a highly disproportionate
distribution, with most isolates belonging to either B. multi-
vorans or B. cenocepacia; in contrast, B. stabilis, B. ambifaria,
and B. anthina were rarely isolated (1, 2, 37, 53, 58). Compel-
ling evidence that B. cepacia complex strains can spread be-
tween CF patients either by social contacts or via hospital
admission was provided by several studies (25, 33, 34, 48).
B. cepacia complex infections have a considerable impact on
clinical outcome, due to the intrinsic antimicrobial resistance
of these organisms and a lack of effective antibiotics. Chronic
pulmonary B. cepacia complex infections are associated with
increased rates of morbidity and mortality and in some patients
are responsible for a dramatic and fatal deterioration of lung
function known as cepacia syndrome (29, 33). Poor outcome in
lung transplant recipients has also led some clinicians to con-
sider these infections as a contraindication to transplantation
(7, 19). Some CF patients may be transiently colonized, and
others may be chronically or asymptomatically colonized, sug-
gesting differences in host response or pathogenic potential
among B. cepacia complex bacteria. Prevention of pulmonary
infection is vital for CF patients; hence, the importance of
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stringent infection control policies, including patient segrega-
tion, has been strongly emphasized (24, 36, 49, 54, 63). How-
ever, it is also recognized that segregation places considerable
social and personal burdens on CF patients and their families.
To clarify how broadly such protocols should be applied, a
more complete knowledge of the distribution, transmissibility,
and clinical impact of B. cepacia complex members is urgently
needed. The degree to which national and international guide-
lines are followed varies among microbiology laboratories (57),
and misidentification of B. cepacia complex is common (45).
Furthermore, due to the taxonomic complexity of these bacte-
ria and the emergence of phenotypically similar species, the
identification of individual genomovars is often a difficult chal-
lenge (10, 11, 43, 56, 64–66).
A better understanding of the epidemiology and pathogenic
potential of B. cepacia complex species is vital to ensure opti-
mal prevention and management of CF lung disease. The goal
of the present study was to evaluate the epidemiology of
B. cepacia complex bacteria infecting CF patients in Italy by
using BOX-PCR analysis and pulsed-field gel electrophoresis
(PFGE) of genomic macrorestriction fragments. The latter
approach has a higher index of discrimination and is opti-
mal for studying local B. cepacia complex epidemiology (3),
whereas BOX-PCR fingerprinting is considered to be more
appropriate for long-term B. cepacia complex epidemiology (3,
12, 15). BOX-PCR fingerprinting is a repetitive element se-
quence-based typing method that differentiates microorgan-
isms by using primers complementary to interspersed repeti-
tive consensus sequences that amplify diverse-sized DNA
fragments between the repetitive BOX elements (47). While
originally detected in Streptococcus pneumoniae (47), BOX
elements with BOX-A1R as the single primer in the PCR assay
were subsequently used as target for PCR-based fingerprinting
in a range of different bacteria, including B. cepacia complex
bacteria (3, 12, 15, 32).
MATERIALS AND METHODS
Bacterial strains. To analyze the prevalence, genomovar status, and epidemi-
ology of the B. cepacia complex in Italy, all patients presumptively colonized by
the B. cepacia complex attending 18 of 20 Italian CF centers from 1997 to 2003
were included in the study. A total of 225 isolates were obtained from sputum
samples of 225 CF patients. All bacterial strains were isolated, following inter-
national guidelines, and were tentatively identified as members of the B. cepacia
complex by commercial tests, including API20NE (Biomerieux, Rome, Italy) and
BBL Cristal (Becton Dickinson, Milan, Italy).
All isolates were stored at 80°C. B. cepacia complex genomovar status was
determined by a polyphasic approach, including whole-cell protein electrophore-
sis and recA restriction fragment length polymorphism (RFLP) analysis by means
of the restriction enzymes HaeIII and MnlI.
SDS-PAGE of whole-cell proteins. Whole-cell protein extracts were prepared,
and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
was performed as previously described (51). The densitometric analysis, normal-
ization, and interpolation of the protein profiles and numerical analyses were
performed with the GelCompar software package (Applied Maths). The Pearson
product moment correlation coefficient was used to calculate similarity levels
between the patterns.
recA RFLP analysis. RFLP analyses were performed as described previously
(43). Electrophoretic separation of the restriction fragments was, however, per-
formed by SDS-PAGE. Briefly, 10 ml of a 40% (wt/vol), 29:1 acrylamide:bisac-
rylamide monomer solution (National Diagnostics) was mixed with 5 ml 10
Tris-borate-EDTA (TBE) buffer and 34.5 ml sterile MilliQ Ultrapure water to
obtain an 8% polyacrylamide gel. PhiX174 DNA/HinfI (Promega) comprising 20
DNA fragments ranging from 24 to 726 bp was used as a size marker. Patterns
were stored and analyzed with the BioNumerics 3.5 software package (Applied
Maths).
Pulsed-field gel electrophoresis analysis. Pulsed-field gel electrophoresis was
performed as described by Butler et al. (5) with the following modifications. A
suspension of bacteria was made in 75 mM NaCl–25 mM EDTA (pH 7.5) (SE
buffer), standardized, and mixed with an equal volume of molten 1.2% low-melt
agarose (Bio-Rad, Hemel Hempstead, United Kingdom). Bacteria were lysed
using lysis buffer containing Triton X-100 (5 l/ml). DNA, restricted with XbaI
and SpeI (Gibco BRL, Paisley, United Kingdom) was separated by PFGE by
using the CHEF DRII system (Bio-Rad) in 0.5 TBE Buffer with pulse times of
2.9 to 35.4 s at 200 V for 20 h at 14°C. Clonality was identified based on the
recommendations of Tenover et al. (61).
BOX-PCR. DNA from each isolate was prepared by heating one colony at
95°C for 15 min in 20 l of lysis buffer containing 0.25% (wt/vol) SDS and 0.05 M
NaOH. Following lysis, 180 l of distilled water was added, and the DNA
solutions were stored at 4°C. Repetitive sequence-based PCR typing with a
BOX-A1R primer (5-CTACGGCAAGGCGACGCTGACG-3) was carried as
described previously (52). Briefly, 1 l of DNA solution was mixed with 2 U of
Taq DNA polymerase (Red Goldstar; Eurogentec), 1.25 l of 25 mM (each) of
deoxynucleoside triphosphates (Pharmacia), 2.5 l of dimethyl sulfoxide, 0.2 l
of bovine serum albumin (10 mg/ml) (Boehringer), 5 l of 5 Gitschier buffer
(52), and 1 l of primer (0.3 g/ml) in a final volume of 25 l. Amplification was
carried out as follows: after initial denaturation for 7 min at 95°C, 30 amplifica-
tion cycles were completed, each consisting of 1 min at 94°C, 1 min at 52°C, and
8 min at 65°C. A final extension of 16 min at 65°C was applied. PCR products
were separated on a 1.5% agarose gel in 0.5 TBE buffer (55 V for 960 min at
4°C). A reference marker comprising a mixture of 100-bp and 500-bp molecular
rulers (Bio-Rad) was used multiple times on each gel to allow normalization.
Following staining with ethidium bromide and visualization by UV illumination,
gels were analyzed with the software package BioNumerics 3.5 (Applied Maths).
Insertion sequence IS1363 PCR. The assay for the detection of insertion
sequence IS1363 (specific for B. cenocepacia strains ET12 and PHDC) was
performed as previously described (40). Briefly, template DNA was prepared as
described above. IS1363-specific PCR was performed with oligonucleotide prim-
ers P1 (5-GCTTAATAGGATGGTCAG-3) and P2 (5-TCCATGACCACC
GTACAACTC-3) that target sequences within IS1363. PCR was performed
in 25-l reaction mixtures containing 2 l of bacterial cell lysate, 1 U of Taq
polymerase (QIAGEN), 0.25 mM deoxynucleoside triphosphates, 0.2 M (each)
primers P1 and P2, and 2.5 l 10 PCR buffer (QIAGEN). Amplification was
carried out by using a PTC-100 programmable thermal cycler (MJ Research)
under the following conditions: 95°C for 2 min; 30 cycles, each consisting of 95°C
for 45 s, 55°C for 45 s, and 72°C for 45 s; and 72°C for 10 min. The resulting
235-bp amplicon was visualized after gel electrophoresis and staining with
ethidium bromide. DNA from B. cenocepacia AU1054 was used as a positive
control.
RESULTS
Species identification. Of 225 isolates, 208 isolates were
confirmed as B. cepacia complex bacteria, representing 73.5%
of Italian CF patients colonized by B. cepacia complex (22, 44).
In 2002, the Italian Register of Cystic Fibrosis reported 3,791
living patients (52a); therefore, the overall prevalence of B.
cepacia complex is 7.5%. To identify non-B. cepacia complex
isolates, whole-cell protein electrophoretic profiles of all iso-
lates were prepared and compared with a database comprising
a large number of gram-negative nonfermenting bacteria that
are regularly misidentified as members of the B. cepacia com-
plex (10, 11, 13). Of the isolates, 10 were identified as Burk-
holderia gladioli, two as Stenotrophomonas maltophilia, one as
Achromobacter xylosoxidans, one as Herbaspirillum huttiense,
one as Inquilinus limosus, and two as Pseudomonas sp. (data
not shown). The misidentified organisms represented 8% of
the received isolates (17 of 225), showing the good perfor-
mance of the Italian laboratories. Among the 208 isolates con-
firmed as B. cepacia complex bacteria, 13 isolates were identi-
fied as B. multivorans and 2 were identified as B. vietnamiensis
by whole-cell protein electrophoresis (data not shown). As the
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latter technique is often not sufficiently discriminatory to dif-
ferentiate isolates belonging to the remaining B. cepacia com-
plex genomovars (10, 11), all B. cepacia complex isolates were
further identified by means of recA RFLP analysis using HaeIII
and MnlI as restriction enzymes (43). Table 1 presents the
distribution of B. cepacia complex species among Italian
centers. Sixteen isolates (7.7%) were identified as B. cepacia
(genomovar I): 11 isolates belonged to HaeIII recA RFLP type
E, 3 isolates belonged to HaeIII-recA RFLP type K, and 2
belonged to a novel HaeIII-recA RFLP type designated Se20.
The 13 B. multivorans isolates (6.3%) belonged to HaeIII-
recA RFLP types F (11 isolates) and R (2 isolates). The
B. cenocepacia isolates represented the major fraction among
the Italian isolates (61.1%) and belonged to HaeIII-recA
RFLP types G (50 isolates), H (21 isolates), I (38 isolates), and
U (18 isolates). Thirteen isolates (6.3%) belonged to B. stabilis
HaeIII-recA RFLP type J. One isolate each (1%) belonged to
B. vietnamiensis HaeIII-recA RFLP types A and B and to
B. ambifaria HaeIII-recA RFLP type L. Nine B. pyrrocinia iso-
lates (4.3%) belonged to HaeIII-recA RFLP type Se13. For 27
isolates (13%), the genomovar status remained undetermined,
as they represented RFLP types for which the taxonomic status
has not yet been clarified; 22 isolates belonged to HaeIII-recA
RFLP type AT (10.6%), 2 (1%) belonged to HaeIII-recA
RFLP type W, and 1 belonged to HaeIII-recA RFLP type S.
Two isolates had well-established HaeIII-recA RFLP profiles
(H and J) but upon digestion of the amplicon by MnlI proved
to be aberrant from the typical type H and J isolates.
Strain typing. To investigate the epidemiology of B. cepacia
complex in Italy over a 7-year period, BOX-PCR fingerprints
were generated for all isolates (3, 12, 15). The reproducibility
of the BOX-PCR fingerprints for isolates representing various
B. cepacia complex species was in the range of 80 to 85%,
which corresponds with results from previous studies (3, 12). In
contrast with other PCR-based typing methods, the discrimi-
natory power of BOX-PCR fingerprinting was not as high as
for PFGE analysis, for instance; however, BOX-PCR profiles
have been found useful for strain typing, as well as for the
identification of infraspecific clusters of strains (23, 41).
For this reason, the similarity cutoff level to identify clonally
related isolates was set as stringently as possible (at 80%) for
all B. cepacia complex species (referred to below as BOX
FIG. 1. BOX-PCR profiles of isolates belonging to the major recA
RFLP types AT, E, G, H, I, J, Se13, and U (lanes 1 to 8).
TABLE 1. Distribution of B. cepacia complex species in 18 Italian centers
B. cepacia complex
species
No. of strains in centera: Total no. (%)
of strainsa b c d e f g h i l m n o p q r s t
B. cepaciab 1 3 3 4 1 3 1 16 (7.7)
B. multivorans 1 4 3 2 2 1 13 (6.3)
B. cenocepacia 7 2 30 2 4 1 18 13 1 5 3 1 7 7 20 6 127 (61.1)
B. stabilis 1 4 1 1 1 2 1 2 13 (6.3)
B. vietnamiensis 1 1 2 (1)
B. ambifaria 1 1 (0.5)
B. pyrrocinia 3 5 1 9 (4.3)
Undetermined 8 3 3 1 6 2 1 2 1 27 (13)
Total 8 3 49 2 5 1 21 24 12 11 11 1 3 2 10 14 23 8 208
a One strain per patient has been isolated.
b B. cepacia constitutes genomovar I.
TABLE 2. Major B. cepacia complex clones identified
by BOX-PCR
BOX
cluster
No. of
isolatesa
HaeIII-recA
RFLP type
B. cepacia
complex species
No. of participating
centers (designation)
1 22 AT Undetermined 8 (n, h, o, g, l, r, i, c)
2 7 E B. cepaciab 4 (m, h, r, c)
3 12 G B. cenocepacia 5 (l, t, o, e, d)
4 31 G B. cenocepacia 7 (h, c, r, g, t, i, q)
5 17 H B. cenocepacia 6 (c, g, q, h, s, m)
6 13 I B. cenocepacia 4 (s, h, c, m)
7 14 I B. cenocepacia 3 (c, h, g)
8 9 J B. stabilis 6 (h, c, i, s, m, q)
9 9 Se13 B. pyrrocinia 3 (i, m, c)
10 17 U B. cenocepacia 6 (a, r, q, g, h, b)
a One isolate per patient has been isolated.
b B. cepacia constitutes genomovar I.
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clusters). Ten major BOX clusters, encompassing the majority
(72.6%) of the isolates examined, were identified. The BOX
profiles of remaining isolates were unique or represented small
clusters comprising two to three isolates (data not shown).
Table 2 gives an overview of the number of isolates belonging
to each of the major BOX clusters, their HaeIII-recA RFLP
type, genomovar, and CF centers involved. Figure 1 illustrates
the BOX-PCR profiles of isolates belonging to the major recA
RFLP types (AT, E, G, H, I, J, Se13, and U), while the HaeIII-
recA RFLP profiles of the same types are shown in Fig. 2. All
208 isolates were subsequently typed by PFGE.
The criteria used to define clonality for PFGE were as de-
scribed by Tenover et al. (61): profiles showing differences of
up to three bands were regarded as closely related, while those
showing a four- to six-band difference were considered to be
possibly related, provided there was an epidemiological link
between the isolates.
BOX-PCR cluster 1 (HaeIII-recA RFLP type AT) included
22 isolates, which were distributed among four PFGE clusters
as follows. Two PFGE clusters were composed of isolates from
the same center (seven and five isolates, respectively), another
PFGE cluster included six isolates from four different centers,
and the last PFGE cluster was composed of three isolates
collected from three centers. The remaining isolate showed a
unique PFGE pattern. Figure 3 shows the four different PFGE
profiles produced by these isolates. The BOX-PCR clone 5
(HaeIII-recA RFLP type H) included 17 isolates representing
three different PFGE clusters composed of 2, 3, and 5 isolates,
respectively. Isolates within each of the PFGE clusters were
from a single center. The remaining seven isolates all had
unique PFGE profiles (data not shown). In addition, we also
investigated all BOX cluster 5 isolates for the presence of
IS1363 using specific IS1363 PCR. All BOX cluster 5 isolates
contained this genetic marker (data not shown).
All but two (seven isolates) of BOX-PCR clone 9 (HaeIII-
recA RFLP type Se13) isolates belonged to a single clone and
were from two different centers. The remaining two isolates in
this group failed to produce any PFGE profile (data not
shown).
Among the remaining isolates examined, several additional
center-specific PFGE clusters were identified, corroborating
results obtained by BOX-PCR analysis (data not shown).
DISCUSSION
The present study reports on the epidemiology of B. cepacia
complex bacteria infecting CF patients in Italy. Strains from
208 out of 283 (73.5%) Italian CF patients colonized by B. cepacia
complex were collected (22, 44; data are from reference 44 and
the present study). In 2002, the Italian Register of Cystic Fi-
brosis reported 3,791 living CF patients (52a); therefore, the
overall prevalence of B. cepacia complex is 7.5%. Similar re-
sults have been reported from previous studies of patients in
Italy (22, 60), confirming the efficacy of the segregation policies
actually adopted by all Italian CF centers (22). Higher preva-
lences (about 20%) have been observed in some Italian centers
and were associated with local spread of B. cenocepacia (1, 44).
Of 208 isolates collected from 208 patients attending 18
Italian CF centers, the majority (61.1%) of isolates belonged to
B. cenocepacia, whereas 4.3 to 7.7% of isolates belonged to
B. cepacia, B. multivorans, B. stabilis, and B. pyrrocinia. The
other genomovars accounted for 1% or fewer of the isolates
received (B. vietnamiensis and B. ambifaria) or were absent
(B. dolosa and B. anthina). These data confirm and extend
results from previous studies of B. cepacia complex bacteria
infecting Italian CF patients (1, 44, 49). About 13% of the
B. cenocepacia isolates belonged to HaeIII-recA RFLP type U,
which was reported as a major problem in the Genoa CF
center (44). The HaeIII-recA RFLP type U isolates of the
FIG. 2. HaeIII-recA RFLP profiles of types AT, E, G, H, I, J, Se13,
and U (lanes 1 to 8).
FIG. 3. PFGE profiles representing the four different clusters within
the 22 isolates of BOX-PCR cluster 1 (HaeIII-recA RFLP type AT).
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present study were obtained from six CF centers throughout
Italy.
This predominance of B. cenocepacia in CF patients in Italy
resembles the situation reported in Canada (80% prevalence)
(58), the United States (50%) (53), the United Kingdom
(76%) (9), and the Prague and Lisbon CF centers in Portugal,
with prevalences of 90% and 52%, respectively (17, 21). Some
national reports showed that other genomovars reach signifi-
cant percentages, such as B. cepacia (genomovar I) in Australia
(29%) (31); B. multivorans in France (51%) (4), the United
States (38%) (37), the United Kingdom (39%) (62), and
Belgium (18); or B. stabilis (54%) in the Slovak Republic (21).
In the present study, the genomovar status of 13% of the
strains was undetermined (Table 1). Isolates belonging to
HaeIII-recA RFLP type AT accounted for most of these iso-
lates. Isolates with the same RFLP type were recovered as
contaminants from dialysis equipment in Brazil (42). BOX-
PCR was chosen as the initial genotyping tool because it was
previously shown that it is a useful tool to study the large-scale
epidemiology of B. cepacia complex bacteria (3, 12). With the
exception of small clusters comprising two to three isolates, 10
major BOX clusters were delineated. An analysis of the iso-
lates by PFGE revealed that each of these BOX clusters com-
prised isolates that were considered unrelated by conventional
criteria (61). This difference in typing resolution for B. cepacia
complex bacteria confirmed previous reports (12). Three BOX
clusters appeared of special interest. We report the first case of
epidemic spread of HaeIII-recA RFLP type AT among CF
patients (BOX cluster 1). The latter clone was isolated from 22
patients in eight CF centers (Table 2) and comprised multiple
clusters of isolates, which were also considered clonal following
interpretation of PFGE patterns.
The 17 BOX cluster 5 isolates were derived from patients in
six CF centers (Table 2). Their BOX fingerprints were identi-
cal to those of strain PHDC (16), a well-characterized epi-
demic B. cenocepacia strain recovered from numerous CF pa-
tients and environmental samples in the United States (8, 39).
The presence of IS1363, an insertion sequence specific for the
highly epidemic strains B. cenocepacia ET12 (HaeIII-recA
RFLP type G) and PHDC (HaeIII-recA RFLP type H) was
confirmed in all BOX cluster 5 isolates. Identification as
PHDC was further confirmed by comparison of random am-
plified polymorphic DNA profiles, as reported previously (16).
Most remarkably, this epidemic clone was recognized in CF
specimens from patients in several other European countries
(16). When examined by PFGE, seven of these isolates repre-
sented a single PFGE cluster and several isolates with unique
profiles.
Finally, BOX cluster 9 comprised nine isolates from three
centers, which were identified as B. pyrrocinia, an organism not
previously associated with spread in CF patients. When exam-
ined by PFGE, these isolates represented two PFGE clusters
(specific for a single center each).
In general, the comparison between the PFGE and BOX-
PCR genotyping data demonstrated that BOX clusters com-
prised isolates from multiple centers representing multiple
PFGE clusters. In contrast, most PFGE clusters comprised
isolates specific for a single center. While the latter is most
likely indicative of intracenter spread through patient-to-pa-
tient contact (1, 2, 6, 44), the former is more difficult to explain.
Although not common, isolates with the same PFGE profile
have been observed in different Italian centers in the present
study (e.g., in one of the HaeIII-recA RFLP type AT clones)
and in a previous study in Italy (1). We consider isolates with
the same BOX-PCR profile but with different PFGE profiles as
examples of recent divergence from a common ancestral strain
(14). Patients may become infected by such isolates through
patient-to-patient transfer or through acquisition from a com-
mon source. The latter implies that such strains would be
widely distributed in the environment and would have the
potential to infect CF patients.
This latter hypothesis is supported by a number of observa-
tions. Govan et al. (27) provided genomic and phenotypic
evidence of a clonal relationship between the B. cepacia type
strain, isolated by W. Burkholder in the 1940s from a decaying
onion, and an isolate recovered over 50 years later from the
respiratory secretions of a patient with CF. In addition,
LiPuma et al. (38) reported the isolation of the PHDC clone
from numerous patients and agricultural soils of several years
(14, 15, 38). These observations confirm that genotypically
diverging B. cepacia complex clones can prevail in environmen-
tal sources and infect CF patients on multiple occasions. Al-
though to our knowledge the highly transmissible B. cenocepa-
cia lineage ET12 has not been isolated from environmental
sources, it has been recovered from CF specimens from pa-
tients in Europe, North America, Australia, and New Zealand
(1, 14, 15, 25, 26, 30, 50, 59) with minor differences in genotype
and phenotypic properties (50). It seems unlikely that this
global distribution can be explained through patient-to-patient
contacts alone. Interestingly, similar evidence is emerging for
other CF pathogens as well. Genotypically diverse isolates of
P. aeruginosa clone C have been recovered from CF, non-CF,
and environmental specimens throughout Europe (20); since
the early 1990s, European-wide clones of Staphylococcus au-
reus have been isolated from CF and non-CF sources without
epidemiological relationships (55).
The present study provides an overview of the prevalence
and distribution of B. cepacia complex species and strains in
Italy and a comparison with other countries. It confirms that
the epidemiology of the B. cepacia complex bacteria in Italy
is mainly characterized by the acquisition and spread of
B. cenocepacia strains and presents the first evidence of spread
of B. pyrrocinia and of a strain belonging to HaeIII-recA RFLP
type AT. Furthermore, our study confirms the presence of
PHDC, an epidemic lineage of B. cenocepacia, in patients from
multiple CF centers in Italy. These findings substantiate pre-
vious reports of the spread of non-B. cenocepacia B. cepacia
complex species including B. cepacia (genomovar I) (3),
B. multivorans (28, 46, 68), and B. dolosa (3). Finally, the oc-
currence of isolates with distinct PFGE profiles but with the
same BOX-PCR profiles suggests the nationwide environmen-
tal distribution of genetically diverging clones.
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